Morgan Stanley
EIDX

Morgan Stanley’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Morgan Stanley’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-26,967
Closed -$3.55M – 7708
2020
Q4 		$3.55M Buy
26,967
+24,865
+1,183% +$2.2M ﹤0.01% 3634
2020
Q3 		$106K Sell
2,102
-2,508
-54% -$113K ﹤0.01% 5408
2020
Q2 		$219K Buy
4,610
+1,304
+39% +$60.6K ﹤0.01% 5036
2020
Q1 		$162K Sell
3,306
-33,530
-91% -$1.71M ﹤0.01% 4959
2019
Q4 		$2.11M Buy
36,836
+22,022
+149% +$1.09M ﹤0.01% 3996
2019
Q3 		$532K Buy
14,814
+14,589
+6,484% +$570K ﹤0.01% 4657
2019
Q2 		$7K Sell
225
-2,204
-91% -$59.7K ﹤0.01% 6253
2019
Q1 		$57K Sell
2,429
-8,746
-78% -$140K ﹤0.01% 5614
2018
Q4 		$154K Sell
11,175
-349
-3% -$4.4K ﹤0.01% 5388
2018
Q3 		$115K Buy
11,524
+2,524
+28% +$41.5K ﹤0.01% 5646
2018
Q2 		$183K Buy
+9,000
New +$189K ﹤0.01% 5570

Morgan Stanley's EIDX Position: Q1 2021 in Review

Morgan Stanley sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 26,967 shares — an estimated $3.55M sold.

Morgan Stanley first reported a position in EIDX in Q2 2018 and held it in 11 quarters. The position peaked at $3.55M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Morgan Stanley reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Morgan Stanley sold 26,967 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $3.55M.
  • Morgan Stanley first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 11 quarters.
  • Morgan Stanley's Eidos Therapeutics, Inc. Common Stock position peaked at $3.55M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Morgan Stanley's 13F filing for Q1 2021, filed 17 May 2021.